Janux Therapeutics (JANX) News Today $30.83 -0.91 (-2.87%) Closing price 04:00 PM EasternExtended Trading$30.84 +0.01 (+0.03%) As of 04:26 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 Time Period Janux Therapeutics, Inc. (JANX): Among Stocks Receiving the Most Insider Love in MarchMarch 25 at 3:39 PM | msn.comWe're Interested To See How Janux Therapeutics (NASDAQ:JANX) Uses Its Cash Hoard To GrowMarch 25 at 10:39 AM | finance.yahoo.com13,498 Shares in Janux Therapeutics, Inc. (NASDAQ:JANX) Acquired by Magnetar Financial LLCMagnetar Financial LLC bought a new position in Janux Therapeutics, Inc. (NASDAQ:JANX - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 13,498 shares of the company's stock, valued at approximatelyMarch 23 at 5:05 AM | marketbeat.comProficio Capital Partners LLC Invests $1.35 Million in Janux Therapeutics, Inc. (NASDAQ:JANX)Proficio Capital Partners LLC acquired a new position in Janux Therapeutics, Inc. (NASDAQ:JANX - Free Report) in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 25,271 shares of the company's stock, valued at aMarch 21, 2025 | marketbeat.comCharles Schwab Investment Management Inc. Increases Stock Position in Janux Therapeutics, Inc. (NASDAQ:JANX)Charles Schwab Investment Management Inc. boosted its position in shares of Janux Therapeutics, Inc. (NASDAQ:JANX - Free Report) by 16.6% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 273,135 shares of the company's stock after buying anMarch 21, 2025 | marketbeat.comIs Janux Therapeutics (JANX) a Worst High-Risk High-Reward Growth Stock to Buy?March 20, 2025 | insidermonkey.comJanux Therapeutics, Inc. (NASDAQ:JANX) Holdings Raised by Skandinaviska Enskilda Banken AB publSkandinaviska Enskilda Banken AB publ boosted its stake in Janux Therapeutics, Inc. (NASDAQ:JANX - Free Report) by 492.2% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 205,167 shares of theMarch 16, 2025 | marketbeat.comJanux Therapeutics (NASDAQ:JANX) Stock Price Up 8.9% - Should You Buy?Janux Therapeutics (NASDAQ:JANX) Trading 8.9% Higher - Still a Buy?March 13, 2025 | marketbeat.comVictory Capital Management Inc. Boosts Stock Holdings in Janux Therapeutics, Inc. (NASDAQ:JANX)Victory Capital Management Inc. boosted its position in Janux Therapeutics, Inc. (NASDAQ:JANX - Free Report) by 715.0% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 242,409 shares of the company's stock after buyingMarch 13, 2025 | marketbeat.comInsiders Are Loading Up on These 4 Biotech Stocks NowMarch 11, 2025 | 247wallst.comJanux Therapeutics (NASDAQ:JANX) Hits New 1-Year Low - Should You Sell?Janux Therapeutics (NASDAQ:JANX) Sets New 12-Month Low - Here's WhyMarch 11, 2025 | marketbeat.comJanux Therapeutics (NASDAQ:JANX) Shares Gap Up Following Insider Buying ActivityJanux Therapeutics (NASDAQ:JANX) Shares Gap Up on Insider Buying ActivityMarch 10, 2025 | marketbeat.comJanux Therapeutics, Inc. (NASDAQ:JANX) Director Buys $3,418,590.12 in StockJanux Therapeutics, Inc. (NASDAQ:JANX - Get Free Report) Director Ra Capital Management, L.P. acquired 110,206 shares of the firm's stock in a transaction that occurred on Friday, March 7th. The stock was purchased at an average price of $31.02 per share, with a total value of $3,418,590.12. Following the completion of the acquisition, the director now owns 10,141,287 shares in the company, valued at $314,582,722.74. The trade was a 1.10 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is available through this hyperlink.March 8, 2025 | marketbeat.comRa Capital Management, L.P. Acquires 341,742 Shares of Janux Therapeutics, Inc. (NASDAQ:JANX) StockJanux Therapeutics, Inc. (NASDAQ:JANX - Get Free Report) Director Ra Capital Management, L.P. purchased 341,742 shares of the firm's stock in a transaction dated Wednesday, March 5th. The shares were bought at an average price of $30.64 per share, with a total value of $10,470,974.88. Following the purchase, the director now owns 9,658,988 shares in the company, valued at $295,951,392.32. The trade was a 3.67 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website.March 8, 2025 | marketbeat.comJANUX THERAPEUTICS Earnings Preview: Recent $JANX Insider Trading, Hedge Fund Activity, and MoreMarch 7, 2025 | nasdaq.comHC Wainwright Expects Lower Earnings for Janux TherapeuticsJanux Therapeutics, Inc. (NASDAQ:JANX - Free Report) - Equities researchers at HC Wainwright decreased their Q1 2025 earnings estimates for Janux Therapeutics in a research report issued to clients and investors on Monday, March 3rd. HC Wainwright analyst S. Ramakanth now forecasts that the compaMarch 7, 2025 | marketbeat.comJanux Therapeutics (JANX) Projected to Post Quarterly Earnings on FridayJanux Therapeutics (NASDAQ:JANX) will be releasing earnings before the market opens on Friday, March 14, Financial Modeling Prep reports.March 7, 2025 | marketbeat.comJanux Therapeutics, Inc. (NASDAQ:JANX) Insider Sells $107,188.10 in StockJanux Therapeutics, Inc. (NASDAQ:JANX - Get Free Report) insider Andrew Hollman Meyer sold 3,334 shares of the business's stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $32.15, for a total value of $107,188.10. Following the sale, the insider now owns 82,139 shares of the company's stock, valued at $2,640,768.85. The trade was a 3.90 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.March 6, 2025 | marketbeat.comJanux Therapeutics, Inc. (NASDAQ:JANX) Insider Andrew Hollman Meyer Sells 3,334 SharesMarch 6, 2025 | insidertrades.comJanux Therapeutics, Inc. (NASDAQ:JANX) Given Consensus Rating of "Buy" by BrokeragesShares of Janux Therapeutics, Inc. (NASDAQ:JANX - Get Free Report) have been assigned a consensus recommendation of "Buy" from the thirteen brokerages that are currently covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a hold rating, ten have givenMarch 6, 2025 | marketbeat.comJanux Therapeutics, Inc. (JANX): Among The Stocks With At Least $30 Million In Insider Spending RecentlyMarch 5, 2025 | insidermonkey.comJanux Therapeutics, Inc. (JANX): Among The Stocks With At Least $30 Million In Insider Spending RecentlyMarch 5, 2025 | msn.comJanux Therapeutics (NASDAQ:JANX) Reaches New 1-Year Low After Analyst DowngradeJanux Therapeutics (NASDAQ:JANX) Sets New 52-Week Low on Analyst DowngradeMarch 3, 2025 | marketbeat.comJanux Therapeutics (NASDAQ:JANX) Given "Buy" Rating at HC WainwrightHC Wainwright restated a "buy" rating and issued a $70.00 price target on shares of Janux Therapeutics in a report on Monday.March 3, 2025 | marketbeat.comHandelsbanken Fonder AB Buys Shares of 12,000 Janux Therapeutics, Inc. (NASDAQ:JANX)Handelsbanken Fonder AB bought a new stake in Janux Therapeutics, Inc. (NASDAQ:JANX - Free Report) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 12,000 shares of the company's stock, valued at approximately $642,00March 2, 2025 | marketbeat.comJanux Therapeutics (NASDAQ:JANX) Price Target Lowered to $41.00 at ScotiabankScotiabank decreased their target price on Janux Therapeutics from $62.00 to $41.00 and set a "sector perform" rating for the company in a research note on Friday.March 1, 2025 | marketbeat.comWedbush Reiterates "Outperform" Rating for Janux Therapeutics (NASDAQ:JANX)Wedbush reiterated an "outperform" rating and issued a $76.00 target price (up previously from $75.00) on shares of Janux Therapeutics in a research report on Friday.March 1, 2025 | marketbeat.comJanux Therapeutics price target raised to $76 from $75 at WedbushMarch 1, 2025 | markets.businessinsider.comJanux Therapeutics (NASDAQ:JANX) Announces Quarterly Earnings Results, Beats Estimates By $0.13 EPSJanux Therapeutics (NASDAQ:JANX - Get Free Report) released its quarterly earnings data on Thursday. The company reported ($0.36) EPS for the quarter, beating the consensus estimate of ($0.49) by $0.13. Janux Therapeutics had a negative net margin of 463.91% and a negative return on equity of 10.47%.February 28, 2025 | marketbeat.comStifel Nicolaus Sticks to Their Buy Rating for Janux Therapeutics Inc (JANX)February 28, 2025 | markets.businessinsider.comJanux Therapeutics price target lowered to $41 from $62 at ScotiabankFebruary 28, 2025 | markets.businessinsider.comJanux Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business HighlightsFebruary 27, 2025 | businesswire.comJanux Therapeutics, Inc. (JANX): Among the Oversold Biotech Stocks to Buy NowFebruary 24, 2025 | insidermonkey.comHealthInvest Partners AB Purchases Shares of 39,573 Janux Therapeutics, Inc. (NASDAQ:JANX)HealthInvest Partners AB acquired a new position in shares of Janux Therapeutics, Inc. (NASDAQ:JANX - Free Report) in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm acquired 39,573 shares of the company's stock, valuedFebruary 24, 2025 | marketbeat.comJanux Therapeutics, Inc. (NASDAQ:JANX) Shares Purchased by Lester Murray Antman dba SimplyRichLester Murray Antman dba SimplyRich raised its stake in Janux Therapeutics, Inc. (NASDAQ:JANX - Free Report) by 205.3% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 24,315 shares of the company's stock aftFebruary 12, 2025 | marketbeat.comabrdn plc Invests $3.43 Million in Janux Therapeutics, Inc. (NASDAQ:JANX)abrdn plc purchased a new position in Janux Therapeutics, Inc. (NASDAQ:JANX - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 64,072 shares of the company's stock, valued at approximately $3,430,000.February 10, 2025 | marketbeat.comJanux Therapeutics, Inc. (NASDAQ:JANX) Given Consensus Recommendation of "Buy" by BrokeragesShares of Janux Therapeutics, Inc. (NASDAQ:JANX - Get Free Report) have been given an average recommendation of "Buy" by the thirteen ratings firms that are covering the firm, Marketbeat reports. One research analyst has rated the stock with a hold recommendation, ten have given a buy recommendatiFebruary 9, 2025 | marketbeat.comInsider Selling: Janux Therapeutics, Inc. (NASDAQ:JANX) Insider Sells 3,334 Shares of StockFebruary 6, 2025 | insidertrades.comJanux therapeutics' chief business officer sells shares worth $140,999February 5, 2025 | msn.comJanux Therapeutics, Inc. (NASDAQ:JANX) Insider Sells $140,994.86 in StockJanux Therapeutics, Inc. (NASDAQ:JANX - Get Free Report) insider Andrew Hollman Meyer sold 3,334 shares of the business's stock in a transaction that occurred on Monday, February 3rd. The shares were sold at an average price of $42.29, for a total transaction of $140,994.86. Following the completion of the sale, the insider now directly owns 82,139 shares in the company, valued at approximately $3,473,658.31. This trade represents a 3.90 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.February 5, 2025 | marketbeat.comJanux Therapeutics (NASDAQ:JANX) Stock Price Up 6.9% - Should You Buy?Janux Therapeutics (NASDAQ:JANX) Trading 6.9% Higher - Here's What HappenedFebruary 5, 2025 | marketbeat.comJanux Therapeutics (NASDAQ:JANX) Trading Down 4.2% - What's Next?Janux Therapeutics (NASDAQ:JANX) Trading Down 4.2% - Should You Sell?February 4, 2025 | marketbeat.comAnalysts Are Bullish on Top Healthcare Stocks: Janux Therapeutics Inc (JANX), Sun Pharmaceutical Industries Limited (IN:SUNPHARMA)February 4, 2025 | markets.businessinsider.comJanux Therapeutics, Inc. (NASDAQ:JANX) Short Interest Up 19.8% in JanuaryJanux Therapeutics, Inc. (NASDAQ:JANX - Get Free Report) was the target of a large growth in short interest in January. As of January 15th, there was short interest totalling 7,680,000 shares, a growth of 19.8% from the December 31st total of 6,410,000 shares. Currently, 16.4% of the shares of the stock are short sold. Based on an average daily volume of 1,050,000 shares, the days-to-cover ratio is currently 7.3 days.February 2, 2025 | marketbeat.comNisa Investment Advisors LLC Trims Stake in Janux Therapeutics, Inc. (NASDAQ:JANX)Nisa Investment Advisors LLC lessened its holdings in shares of Janux Therapeutics, Inc. (NASDAQ:JANX - Free Report) by 41.7% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 11,867 shares of the company's stock afterJanuary 29, 2025 | marketbeat.comJanux Therapeutics names Zachariah McIver, D.O., Ph.D. as Chief Medical OfficerJanuary 25, 2025 | markets.businessinsider.comJanux Therapeutics Names McIver as Chief Medical OfficerJanuary 24, 2025 | marketwatch.comJanux Therapeutics Promotes Zachariah McIver, D.O., Ph.D. to Chief Medical OfficerJanuary 24, 2025 | businesswire.comJanux Therapeutics (NASDAQ:JANX) Shares Up 6.2% - Here's WhyJanux Therapeutics (NASDAQ:JANX) Shares Up 6.2% - What's Next?January 23, 2025 | marketbeat.comAnalysts Offer Predictions for JANX FY2025 EarningsJanux Therapeutics, Inc. (NASDAQ:JANX - Free Report) - Investment analysts at Cantor Fitzgerald issued their FY2025 earnings per share estimates for Janux Therapeutics in a note issued to investors on Tuesday, January 21st. Cantor Fitzgerald analyst J. Schimmer anticipates that the company will pJanuary 22, 2025 | marketbeat.com Remove Ads Get Janux Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for JANX and its competitors with MarketBeat's FREE daily newsletter. Email Address JANX Media Mentions By Week JANX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. JANX News Sentiment▼1.060.62▲Average Medical News Sentiment JANX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. JANX Articles This Week▼74▲JANX Articles Average Week Remove Ads Get Janux Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for JANX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies RVMD News Today LNTH News Today LEGN News Today TGTX News Today BBIO News Today AXSM News Today TLX News Today BPMC News Today GRFS News Today NUVL News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:JANX) was last updated on 3/25/2025 by MarketBeat.com Staff From Our PartnersYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredDOGE officially begins retirement transformationElon Musk's Department of Government Efficiency ("DOGE") just announced the first-ever "fully digital retireme...Altimetry | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Janux Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Janux Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy JANX Stock Free JANX Stock Alerts